DDInter122 DDInter1615
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Rolapitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Rolapitant may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide
Rolapitant may lead to a major life threatening interaction when taken with Betrixaban